Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2026
Request Brochure for Report -
Increase in Government Participation in Design & Implementation of Comprehensive Vaccination Programs to Propel Market
Pneumococcal disease is considered to be the most common cause of mortality across the globe. The infection is more common in children; however, the disease also affect adults. Demand for pneumococcal vaccines is high across the emerging & developed countries. Moreover, governments have increased focus on the construction of systematic vaccination programs in their respective countries. Public hospitals of Hospital Authority (HA) in Hong Kong participated in the 13-valent pneumococcal conjugate vaccine (PCV13) program in July 2017 which was announced by the Centre for Health Protection to strengthen the immunity of adults against pneumococcal infection. The HA provided pneumococcal vaccination to elderly persons in the country in 2017–2018.
Increase in Investments by Public & Private Players in R&D of Pneumococcal Conjugate Vaccines
Vaccines are considered to be one of the most cost-effective health interventions for infectious diseases. Vaccine companies focus on improving accessibility of vaccines for people living in middle- to low-income countries. The size of their pipeline portfolios is an indication of their efforts. Innovations in the field of medicine have enabled the development of multivalent pneumococcal vaccines. Addressing vaccine affordability and aligning supply & demand have become a priority for vaccine manufacturers. According to the Access to Medicine Foundation, around 30% of adaptive R&D ongoing projects involve multivalent vaccines. Serum Institute of India is developing a 10-valent PCV (pneumococcal conjugate vaccine) that targets the serotype prevalent in 70% of the pneumococcal disease-affected population in Asia, Africa, and Latin America. Innovative and tailored strategies developed by government authorities for pneumococcal vaccination programs are propelling investments by key players in strengthening their pipeline portfolios. Pfizer received three approvals for R&D projects of vaccines targeting meningococcal and pneumococcal diseases in 2017. GlaxoSmithKline is currently characterizing the thermostability of its leading PCV “Synflorix”.
Request for Analysis of COVID19 Impact on Pneumococcal Vaccines Market -
Longer Timeline and High Cost of Development of Pneumococcal Vaccines to Restrain Market
Vaccine development remains a time-consuming and challenging part of the field of medicine, in terms of time required for the discovery of vaccine candidates to market launch. Regulatory constraints increase as the vaccine candidate makes its way through the approval process. Hence, despite achieving the technological advancements in the vaccine development process, some companies are still unable to develop vaccines in a timely manner. Research programs for pneumococcal vaccine development require high capital, which needs strong risk-bearing sponsors and investors. This is considered to be a major restraint of vaccine development. Large pharmaceutical companies such as Pfizer, Inc. and GlaxoSmithKline have made significant investments in the research of pneumococcal vaccines and are often able to claim some returns, which is not possible for emerging companies. Hence, time and cost constraints are expected to hamper the growth of the global pneumococcal vaccines market during the forecast period.
Buy Pneumococcal Vaccines Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=52146<ype=S
Asia Pacific Market to Grow at a Rapid Pace
In terms of revenue, the pneumococcal vaccines market in Asia Pacific is projected to expand at a CAGR of 9.7% during the forecast period. Rapidly increasing patient population and advancements in the biopharmaceutical industry in the region are expected to boost the demand for pneumococcal vaccines, which in turn is likely to drive the market during the analysis period. Additionally, rise in government investment to increase vaccination programs in the region are anticipated to provide lucrative opportunities for manufacturers in the next few years. Moreover, several regional players in China, India, and Southeast Asia are focusing on research & development to bring new products to market. Serum Institute of India in developing 10-valent pneumococcal vaccine. Walvax in China already has 23-valent PPSV in the market and is developing 13-valent pneumococcal vaccine.
Pfizer, Inc. and Merck KGaA to Lead Market
The report also provides profiles of leading players operating in the global pneumococcal vaccines market. These include Pfizer, Inc., Merck & Co., Inc., SK Chemicals, Serum Institute of India Pvt., Ltd., Chengdu Institute of Biological Products Co., Ltd., GlaxoSmithKline plc, Sanofi, and Walvax Biotechnology Co., Ltd. Increase in mergers & acquisitions, strategic collaborations, and new product launches are expected to drive the global market during the forecast period. In September 2018, Pfizer, Inc. announced the grant of Breakthrough Therapy designation by the U.S. FDA for its pipeline candidate pneumococcal vaccine conjugate (20vPnC) - PF-06482077 for adults (18 years and above). Pfizer, Inc. plans to initiate phase-3 trials of the candidate by the end of 2018.
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2026 here
News-ID: 2152069 • Views: 651
More Releases from Transparency Market Research - Pharmaceutical
Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Global Neurovascular Devices Market: Overview The global population is aging rapidly. According to WHO, the chances of health risks are greater in geriatric people than the young generation. Old age is considered to be one of the biggest risk factors that are responsible for developing various diseases such as cardiovascular and neurological conditions. It is because of these factors, the global neurovascular devices market is experiencing robust growth in the
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from …
Swab and Viral Transport Medium Market: Introduction Transparency Market Research has published a new report titled, ‘Global Swab and Viral Transport Medium Market ’. According to the report, the global swab and viral transport medium market was valued at US$ 0.9 Bn in 2019 and is projected to expand at a CAGR of ~3% from 2020 to 2030. Viral transport medium (VTM) enables safe transfer of viruses, chlamydia, and mycoplasma for
Radiofrequency Ablation Devices Market by Product, Geography and Forecast to 202 …
Transparency Market Research (TMR) has published a new report titled, 'Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027'. According to the report, the global radiofrequency ablation devices for pain management market was valued at US$ 543.0 Mn in 2018 and is projected to expand at a CAGR of above 11.0% from 2019 to 2027. Overview Radiofrequency ablation is a minimally invasive surgical
Antithrombin Market Estimated to Flourish by 2025
As per estimates presented in a report by TMR, the demand global antithrombin market will rise at a CAGR of 5.2% for the forecast period of 2017 to 2025. The market for antithrombin is predicted to attract a revenue of US$704.5 mn by the end of 2025 from US$448.2 mn in 2016. The global Antithrombin market is consolidated in nature with a few small-scale vendors that operate in regional markets and
More Releases for Vaccine
Flu Vaccine (Influenza Vaccine) Market: A look into the future of the “Univers …
Latest update on Flu Vaccine (Influenza Vaccine) Market Analysis Report published with an SMI, the industry growth analysis, and Projection by 2021-2028. This report is highly predictive as it holds the overall market analysis of the topmost companies in the Flu Vaccine (Influenza Vaccine) industry. With the classified Flu Vaccine (Influenza Vaccine) market research based on various growing regions, this report provides leading players' portfolios along with sales, growth, market
Rise in the prevalence of infectious diseases, increase in immunization programs across the globe, and surge in R&D activities to develop new vaccine drive the growth of the global vaccine market. Global Vaccines Market was pegged at $32.46 billion in 2019, and is anticipated to hit $54.15 billion by 2027, registering a CAGR of 6.6% from 2020 to 2027. The report provides an in-depth analysis of the top investment pockets, top
US Flu Vaccine [Influenza Vaccine] Market Research Report 2020
DPI Research offers a latest published report on “Influenza Vaccines in the United States – Market Size, Trends, Opportunities and Growth Potential” delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key US flu vaccines market players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze
Measles Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Measles Vaccine Market Production and Demand Analysis 2019 to 2025 Measles Vaccine Market 2019 Manufacturing Analysis and Development Forecast 2025 Measles Vaccine Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025 Measles Vaccine Market to Insight By 2025: Top Key Vendors The global Measles Vaccine market is valued at million US$ in 2018 and will reach million US$ by the
Monovalent vaccine segment to accumulate maximum Paediatric Vaccine Market share
According to a new report published by Future Market Insights titled “Paediatric Vaccine Market: Global Industry Analysis & Opportunity Assessment, 2016 – 2026”, in terms of revenue, the global paediatric vaccine market is expected to increase at 12.2% CAGR during the forecast period 2016-2026. The global paediatric vaccine market is expected to reach US$ 27.97 Bn in 2016. Paediatric vaccine market is a billion dollar market accounting for a substantial proportion
Key Tools for Innovative Vaccine Designs: Vaccine Adjuvants
The report “NORTH AMERICA VACCINE ADJUVANTS MARKET” provides the detail description of market segmentation, applications, growth, size, and outlook. The market is projected to reach USD $278 Million by 2024, at a CAGR of 11.3%. An adjuvant is an immunological agent, which modifies the effect of other agents. Adjuvants can also act as an irritant, which engages and amplifies the body immune response. Adjuvants are added to vaccines to boost the